EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Predictive Biomarkers for Immunotherapy in Endometrial Carcinoma

Cristina Pizzimenti iD, Vincenzo Fiorentino iD, Ludovica Pepe, Mariausilia Franchina iD, Chiara Ruggeri, Alfredo Ercoli, Giuliana Ciappina iD, Massimiliano Berretta iD, Giovanni Tuccari iD, Antonio Ieni iD

Cancers · 22.07.2025 · 17 (15) · 2420

DOI: 10.3390/cancers17152420 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.07.2025. Verfasst von Cristina Pizzimenti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pathology, Department of Human Pathology in Adult and Developmental Age 'Gaetano Barresi', University of Messina, 98125 Messina, Italy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial carcinoma (EC) is the most common gynaecological malignancy in developed nations, exhibiting significant molecular heterogeneity that impacts prognosis and treatment response, particularly in advanced or recurrent settings. Traditional classification is increasingly supplemented by molecular subtyping (POLE-ultramutated, MSI-high/dMMR, NSMP, p53-mutated/CNH), which provides crucial prognostic information and predicts benefit from immunotherapy. This review summarizes the landscape of predictive biomarkers for immune checkpoint inhibitor (ICI) therapy in EC, emphasizing a new therapeutic scenario for advanced and recurrent EC. Mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), leading to high tumor mutational burden (TMB) and increased neoantigen production, is the most established predictor, resulting in FDA approvals for pembrolizumab and dostarlimab in this subgroup. POLE mutations also confer hypermutation and high immunogenicity, predicting a favorable ICI response. Other biomarkers, including PD-L1 expression and TMB, show variable correlation with response and require further standardization. The tumor immune microenvironment, including tumor-infiltrating lymphocytes (TILs), also influences treatment outcomes. Clinical trials have demonstrated significant survival benefits for ICIs combined with chemotherapy (e.g., dostarlimab/pembrolizumab + carboplatin/paclitaxel) in first-line settings, especially for dMMR/MSI-H EC, and for ICI combinations with targeted agents (e.g., lenvatinib + pembrolizumab) in previously treated patients. Integrating molecular classification and validated biomarkers is essential for optimizing patient selection and developing personalized immunotherapy strategies for EC.

Schlagwörter

Stichwörter der Autor:innen

endometrial carcinomaimmune checkpoint inhibitorimmunotherapymismatch repair deficiencytargeted therapies

Autor:innen und Institutionen

  • Section of Pathology, Department of Human Pathology in Adult and Developmental Age 'Gaetano Barresi', University of Messina, 98125 Messina, Italy.
  • Section of Gynecology and Obstetrics, Department of Human Pathology in Adult and Developmental Age 'Gaetano Barresi', University of Messina, 98125 Messina, Italy.
  • Section of Experimental Medicine, Department of Medical Sciences, University of Ferrara, Via Fossato di Mortara, 70, 44121 Ferrara, Italy.
  • Section of Oncology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.

ORCID-Profile: Cristina Pizzimenti, Vincenzo Fiorentino, Mariausilia Franchina, Giuliana Ciappina, Massimiliano Berretta, Giovanni Tuccari, Antonio Ieni

Zitieren

APA

Pizzimenti, C., Fiorentino, V., Pepe, L., Franchina, M., Ruggeri, C., Ercoli, A., Ciappina, G., Berretta, M., Tuccari, G., & Ieni, A. (2025). Predictive Biomarkers for Immunotherapy in Endometrial Carcinoma. Cancers, 17(15), 2420. https://doi.org/10.3390/cancers17152420

Vancouver

Pizzimenti C, Fiorentino V, Pepe L, Franchina M, Ruggeri C, Ercoli A, et al. Predictive Biomarkers for Immunotherapy in Endometrial Carcinoma. Cancers. 2025;17(15):2420. doi:10.3390/cancers17152420

BibTeX
@article{Pizzimenti2025,
  author = {Pizzimenti, Cristina and Fiorentino, Vincenzo and Pepe, Ludovica and Franchina, Mariausilia and Ruggeri, Chiara and Ercoli, Alfredo and Ciappina, Giuliana and Berretta, Massimiliano and Tuccari, Giovanni and Ieni, Antonio},
  title = {Predictive Biomarkers for Immunotherapy in Endometrial Carcinoma},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {15},
  pages = {2420},
  doi = {10.3390/cancers17152420}
}
Kostenlos starten →